Today talk, page-21

Geez, Big Dan, you've got my head working overtime now! But, I think it's best that I address the nagging issue I've had (or rather my lack of understanding) about the so-called "in-house" CarT therapy assets that are presented under the OmniCar platform. I just haven't quite been able to work out the significance of them within the big picture. I kind of thought that the AML, Her2 and GBM therapies would form part of the "proof" yet to be trotted out (if PTX needs to be the pioneer therapy provider to showcase the OmniCar technology at work in a trial)....



Taking the timelines of our three CarT therapies and Cell Therapy Enhancements into account, I would hazard a guess that PTX intend taking any or all three of our drugs to Phase 1 trial/s, if the pre-clinical research justifies it... and in conjunction with any cell therapy enhancement developments we can!

Now, what you have outlined is very much on the cards, Dan. Steve has mentioned many times that they are talking with third parties. I recall in one of the first few presentations I watched a couple of months ago, Steve saying that whilst the big companies with CarT therapies are not expressing open interest (or to that effect) at this stage, he inferred they soon will because its highly likely that smaller companies will want to partner with us in using OmniCar. That concurs with what Rebecca Lim said in her last interview... that she will be looking for potential collaborators at the upcoming Asia Conference - amongst the small, innovative biotech companies similar to us. It will be information she garners from BIg Pharma end of town that will present there that may provide her with some new insight about the directions things are moving.

Everything about this company, to use your words, Dan, is the "real deal". The licences, the IP, the patents, the expertise, the technologies, ... indeed, the real deal. Going by the chart, the pieces of the puzzle for this company have only just started to come together this year with quite a masterpiece (fingers crossed) to be unveiled next year. There's certainly a masterplan playing out here and there's nothing to suggest it won't succeed. Exciting times for an exciting compand and its SH.